Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 13c

Eagle Pharmaceuticals Reports Second Quarter 2021 Results

August 9, 2021 6:50 AM EDT

Q2 2021 net income was $0.28 per basic and $0.27 per diluted share and adjusted non-GAAP net income was $0.95 per basic and $0.93 per diluted share

Announced licensing agreement for U.S. commercial rights to Landiolol, a beta-1 adrenergic blocker and a leading hospital emergency use product in Europe and Japan

Responded to CRL for vasopressin and anticipates commercial launch by year-end; vasopressin patent trial decision expected around mid-September

FDA maintained Priority Review for the Companys Abbreviated New Drug Application (ANDA) for vasopressin and assigned a GDUFA date of December 15,... More